Nxera Pharma will receive a US$8.6 million milestone payment from Centessa after Centessa (now a wholly-owned Eli Lilly subsidiary) achieved a late-stage development milestone. The update is a positive near-term cash flow catalyst, but it is not indicative of broader financial guidance changes.
Nxera Pharma will receive a US$8.6 million milestone payment from Centessa after Centessa (now a wholly-owned Eli Lilly subsidiary) achieved a late-stage development milestone. The update is a positive near-term cash flow catalyst, but it is not indicative of broader financial guidance changes.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
